

Program at a Glance

Date	Time	Session	Chairperson	Speaker	Title
July 10th	18:00-18:10	Welcome Address			
	18:10-19:30	Keynote Lectures	Alice T. Shaw Hiroyuki Mano	Hiroyuki Mano (National Cancer Center Research Institute)	Construction of Cancer Genomic Medicine Platform in Japan
				Alice T. Shaw (Massachusetts General Hospital, Harvard Medical School)	Evolution of Resistance and Tumor Heterogeneity in ALK-Positive Lung Cancer
19:50-21:50	Welcome Party				
July 11th	8:30-10:00	1. Personalized treatment strategies in lung cancer	Alexander Drilon Koichi Goto	Shinji Kohsaka (National Cancer Center Research Institute)	Application of a High-throughput Functional Evaluation of Variants of Unknown Significance to Personalized Medicine
				Alexander Drilon (Memorial Sloan Kettering Cancer Center)	Advances in Targeted Therapy For Driver-Positive Subsets of Non-Small Cell Lung Cancers
				Koichi Goto (National Cancer Center Hospital East)	Development of a Nationwide Genomic Screening Project (LC-SCRUM-Japan) for the Establishment of Precision Medicine in Lung Cancer
	10:00-10:20	Break			
	10:20-11:50	2. Latest advances in small cell lung cancer and mesothelioma	Charles M. Rudin Hiroyuki Aburatani	Charles M. Rudin (Memorial Sloan Kettering Cancer Center)	Latest Advances in Small Cell Lung Cancer
				Hiroyuki Aburatani (The University of Tokyo)	Comprehensive Molecular Analysis of Malignant Pleural Mesothelioma
				Shoutaro Tsuji (Kanagawa Cancer Center Research Institute)	Development of Precise Diagnosis with a New Mesothelioma Marker, Sialylated HEG1
	11:50-12:50	Lunch and Poster View			
	12:50-14:20	Poster Presentation			
	14:20-15:50	3. Targeting KRAS-mutant lung cancer	Ferdinandos Skoulidis Hiroyuki Nagase	Ferdinandos Skoulidis (The University of Texas MD Anderson Cancer Center)	Dissecting Immunotherapy Responses in Subgroups of KRAS-Mutant Lung Adenocarcinoma
Hiromichi Ebi (Aichi Cancer Center Research Institute)				Combination Therapies Targeting KRAS Mutant Lung Cancer	
Hiroyuki Nagase (Chiba Cancer Center Research Institute, Chiba University)				Targeting the RAS Gene against Cancer	
15:50-16:10	Break				
16:10-17:40	4. Overcoming resistance to targeted therapies in lung cancer	Christine Lovly Takashi Takahashi	Takashi Takahashi (Nagoya University)	ROR1: An Achilles Heel of Lung Cancer	
			Christine Lovly (Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center)	Overcoming Resistance to Mutant-Selective EGFR Inhibition in EGFR-mutant Lung Cancer	
			Ryohei Katayama (Cancer Chemotherapy Center, JFCR)	Drug Repurposing: Overcoming the Acquired Resistance with Other Target Inhibitors	
18:00-19:00	Meet-the Expert Evening (all participants)				
19:30-21:30	Banquet				

Date	Time	Session	Chairperson	Speaker	Title
July 12th	8:30-10:00	5. Novel immunotherapy strategies: Beyond PD-1/PD-L1	Justin F. Gainor Hiroyoshi Nishikawa	Hiroyoshi Nishikawa (Research Institute/EPOC, National Cancer Center, Nagoya University)	Complexed Immune Suppressive Mechanisms in Tumor Microenvironment
				Justin F. Gainor (Massachusetts General Hospital)	Emerging Immunotherapy Combinations in the Management of Non-Small Cell Lung Cancer
				Koji Tamada (Yamaguchi University)	Revolution of CAR-T Cell Technology to Develop Next-generation Cancer Immunotherapy
10:00-10:20	Break				
10:20-11:50	6. Primary and acquired mechanisms of resistance to immunotherapies	Roy S. Herbst Heiichiro Udono	Kenji Chamoto (Kyoto University)	The Role of Fatty Acid Oxidation of T Cells in the Synergistic Effect With PD-1 Blockade	
			Heiichiro Udono (Okayama University)	Anti-diabetes Drug, Metformin, Drives Metabolic Reprogramming of Tumor Microenvironment, Leading to Inhibition of Tumor Growth	
			Roy S. Herbst (Yale Cancer Center/Yale School of Medicine/Smilow Cancer Hospital)	Primary and Acquired Mechanisms of Resistance to Immunotherapies	
11:50-12:50	Lunch				
12:50-14:20	7. Tumor heterogeneity and circulating tumor DNA	Maximilian Diehn Seiji Yano	Seiji Yano (Cancer Research Institute, Nano Life Science Institute, Kanazawa University)	Inter-organ Heterogeneity on Mechanisms of Targeted Drug Resistance - Central Nervous System (CNS) vs extra CNS-	
			Maximilian Diehn (Stanford University School of Medicine)	Circulating Tumor DNA Analysis for Personalized Cancer Detection and Monitoring	
			Tsukasa Kadota (National Cancer Center Research Institute, The Jikei University School of Medicine)	Circulating MicroRNAs as Biomarkers for Early Detection and Prediction of Immunotherapeutic Response in Lung Cancer Patients	
14:20-14:40	Break				
14:40-16:10	8. Tumor microenvironment and implications for treatment	Miguel F. Sanmamed Kohei Miyazono	Atsushi Enomoto (Nagoya University)	Heterogeneity of Cancer-Associated Fibroblasts and its Significance in Tumor Progression and Response to Therapies	
			Miguel F. Sanmamed (Yale School of Medicine)	Modeling Patient-derived Lung Tumor Microenvironment To Develop Immunotherapies	
			Kohei Miyazono (The University of Tokyo)	Regulation of the Development of Lung Cancer by TGF- β Signaling	
16:10-16:20	Closing Remarks				